CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Active taVNS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04157621
NCT04157621N/ACompleted
CompareCT.gov

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Mild to Moderate Parkinson's Disease

Medical University of South Carolina·interventional·Posted Nov 8, 2019·Updated Jan 25, 2023

In Brief

A clinical study evaluating Active taVNS and Sham Stimulation for Parkinson Disease. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to find out whether a non-invasive form of nerve stimulation called transcutaneous vagus nerve stimulation (taVNS) is safe and effective in people with Parkinson's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 8, 2019
Enrollment StartMar 20, 2018
Primary CompletionJun 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.6 years ago

Interventions

Active taVNSdevice

Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus

Sham Stimulationdevice

Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.